Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.76 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22720093 | 1.00 | KRAS (0.76) | KRASSOS1 | |
| SCHEMBL22967714 | 0.93 | KRAS (0.73) | KRASSOS1 | |
| SCHEMBL23282062 | 0.93 | KRAS (0.73) | KRASSOS1 | |
| SCHEMBL23282077 | 0.93 | KRAS (0.76) | KRASSOS1 | |
| SCHEMBL23282037 | 0.93 | KRAS (0.76) | KRASSOS1 | |
| SCHEMBL22725420 | 0.93 | KRAS (0.70) | KRASSOS1 | |
| SCHEMBL29239874 | 0.92 | KRAS (0.76) | KRASSOS1 | |
| SCHEMBL29581987 | 0.92 | KRAS (0.76) | KRASSOS1 | |
| SCHEMBL29239870 | 0.92 | KRAS (0.76) | KRASSOS1 | |
| SCHEMBL22720048 | 0.91 | KRAS (0.74) | KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-02-11 | — | — | US | disclosed |
| WO-2021023247-A1 | KRAS MUTANT PROTEIN INHIBITOR | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020238791-A1 | HYDROPYRIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | KRAS 1/4885SOS1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.